A. A. Sinitsyna

A. A. Sinitsyna

Auto-generated profile, based on publicly available information

A. A. Sinitsyna

Semashko National Research Institute of Public Health; Sechenov First Moscow State Medical University (Sechenov University)

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2020 in Drug development & registration
Verified
Journal Article
Open access
PDF file
АПА. Г. Пальвинский
А. Г. Пальвинский
EBElena Bakhrushina
Elena Bakhrushina
ZKZ. M. Kozlova
Z. M. Kozlova
ASA. A. Sinitsyna
A. A. Sinitsyna
I(Ivan I. Krasnyuk (Jr.)
Ivan I. Krasnyuk (Jr.)
Introduction. Dental gel is one of the modern dosage forms with optimal biopharmaceutical properties for the treatment and prevention of oral diseases An isoquinoline alkaloid berberine is the promising active substance with antibacterial and anti-inflammatory effect, capable of forming stable dispersed systems with gel-forming components. It is noteworthy that, despite the pronounced antimicrobial activity of the alkaloid berberine, there is currently no dental dosage form with this component on the pharmaceutical market, and therefore research in this direction is of great interest.Aim. Selection of the optimal technology for obtaining dental gel with berberine for the treatment of oral diseases.Materials and methods. Berberine bisulfate (manufactured by CJSC «Vifitech», Obolensk, Moscow region, RF), poloxamers P407 and P338 (EP, USP/N; BASF, Germany), propylene glycol (USP; BASF, Germany), sodium chloride (Sigma-Aldrich, Germany, Cat. No. S9888), mucin type II from a pig stomach (Sigma-Aldrich, Germany, Cat. No. M2378). In the development of the composition and technology for the preparation of gels, a magnetic stirrer with a temperature control function (C-MAG HS 7 from IKA, Germany) was used. Gels were prepared by the «hot method» and «cold method».Results and discussion. The production of the gel by the «hot method» provided a uniform dosage form. The obtained pH value is within the range of optimal diapason. Measurement of the specific peel force of the model gel sample showed pronounced mucoadhesive properties, which indicates that there is no need to adjust this parameter by introducing additional components into the formulation. The spectroscopic method is applicable for the analysis of berberine gel. It has been found that a significant dilution of the reference substance sample is required to develop an identification procedure.Conclusion. The production of a sample of the dosage form by the «hot method» is optimal, which is probably due to the effect of solubilization and better distribution of the active substance in the base.

30 March 2023 in "Medical & Pharmaceutical Journal "Pulse"
Verified
Journal Article
Closed access
SASinitsyna A.A.
Sinitsyna A.A.
DMDenisova M.N.
Denisova M.N.
LTLitvinova T.M.
Litvinova T.M.
GIGlazkova I.U.
Glazkova I.U.
NGNesterov G.V.
Nesterov G.V.
Aim. Identification and analysis of the reasons for the refusal to dispense drugs to the adolescent population. Material and methods. Sociological research was conducted by the survey method (questionnaire) using the Google Forms service. The questionnaire consisted of 3 closed questions and an open question. Statistical processing of the data results was carried out using the SPSS program. Results. 12 reasons why pharmacists refuse to purchase over-the-counter drugs for adolescents were identified: age (26.32%), lack of a doctor's prescription (14.74%), lack of information about the drug being purchased (17.74%), low medical literacy (10.53%), use of information from unverified sources (7.37%), suspicion of acquisition for the purpose of abuse (6.32%), discrepancy between the described symptoms and indications for the use of drugs (5.26%), the teenager causes doubts (4.21%), lack of parental consent and the ability to contact them (4.21%), purchase of certain groups of drugs or individual drugs (4.21%), a large number of packages of drugs (1.05%), contraindications for age (1.05%). 70.37% of respondents refuse to dispense to all minors, 25.93% - up to 14 years old and 3.70% up to 16 years old. 11.11% erroneously stated that the sale of over-the-counter drugs to teenagers is prohibited by law. Conclusion. In the absence of a regulatory and legal framework, pharmacists refuse to sell medicines for adolescents based on their experience and internal code of ethics. In a such situation, it is the most appropriate to develop an algorithm for pharmaceutical counseling in pharmacies.

30 July 2025 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
MDM. N. Denisova
M. N. Denisova
ASA. A. Sinitsyna
A. A. Sinitsyna
Introduction. Access to modern methods of treatment and, consequently, innovative medicines, is one of the main indicators of the pharmaceutical industry development in the country and the healthcare system as a whole. The concept of “accessibility of medicines” can be considered in two aspects: physical and economic. Breast cancer confidently occupies the first place in the structure of oncological diseases among women. Since the beginning of 2023, doctors have identified 77 000 cases of breast cancer in Russia.Aim. To assess the availability of innovative drugs used for the treatment of breast cancer on the Russian market.Materials and methods. Data from open information sources were used as the analysis material: the IQVIA database; data on clinical trials in Europe and the USA; clinical guidelines of the Russian Federation. A search was also carried out in the scientific electronic libraries eLibrary and PubMed.Results. From 2018 to 2023, the FDA approved 8 drugs and one diagnostic medicine for breast cancer. The European Agency has registered 6 medicines over the same 5-year period. In the Russian Federation, only three of these drugs have reached registration, and two more remain in Russian clinical trials with the status of “ongoing”.Conclusions. Only one drug, Talazoparib (Talcenna, Pfizer), can be considered available to a Russian patient according to accepted criteria. Over the past 5 years, breast cancer therapy has focused on the new innovative drugs that have shown high efficacy in the treatment of severely treated patients or superior efficacy in comparison with established therapy algorithms.